去甲万古霉素治疗耐甲氧西林金黄色葡萄球菌 医院获得性肺炎的临床疗效

目的 观察去甲万古霉素治疗耐甲氧西林金黄色葡萄球菌（MRSA）医院获得性肺炎的临床疗效。方法 选择2013年8月~2018年10月我院收治的MRSA医院获得性肺炎患者68例，随机分为观察组（37例）和对照组（31例）。观察组给予去甲万古霉素治疗，对照组给予利奈唑胺治疗，比较两组临床疗效、细菌学转归及不良反应情况。结果 观察组总有效率为86.49%，低于对照组的70.27%，但差异无统计学意义（P＞0.05）。观察组细菌总清除率为70.27%，低于对照组的70.97%，但差异无统计学意义（P＞0.05）。观察组不良反应发生率为29.73%，高于对照组的25.81%，但差异无统计学意义（P＞0.05）。结论 对于MRSA医院获得性肺炎的治疗，去甲万古霉素疗效和安全性与利奈唑胺相似。

Clinical Efficacy of Norvancomycin in the Treatment of Methicillin-resistant Staphylococcus Aureus Hospital Acquired Pneumonia

Abstract:Objective To observe the clinical efficacy of norvancomycin in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) hospital-acquired pneumonia.Methods A total of 68 patients with MRSA hospital acquired pneumonia admitted to our hospital from August 2013 to October 2018 were randomly divided into observation group (37 cases) and control group (31 cases). The observation group was treated with norvancomycin, and the control group was treated with linezolid. The clinical efficacy, bacteriological outcome and adverse reactions were compared between the two groups.Results The total effective rate of the observation group was 86.49%, which was lower than that of the control group 70.27%, but the difference was not statistically significant (P>0.05). The total bacterial clearance rate of the observation group was 70.27%, which was lower than that of the control group 70.97%, but the difference was not statistically significant(P>0.05). The incidence of adverse reactions in the observation group was 29.73%, which was higher than 25.81% in the control group, but the difference was not statistically significant(P>0.05).Conclusion The efficacy and safety of norvancomycin is similar to linezolid for the treatment of acquired pneumonia in MRSA hospitals.